Skip to main content

Erratum to: Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain

The Original Article was published on 28 August 2014

Erratum

The authors would like to issue an erratum for this article [1], and would like to declare the following competing interests which we inadvertently failed to include in our original publication. The authors would like to apologise for this omission.

Competing interests

Dr. Salvatore Cuzzocrea, researcher on the study team, is co-inventor on patent WO2013121449 A8 (Epitech Group SpA) which deals with compositions and methods for the modulation of amidases capable of hydrolysing N-acylethanolamines useable in the therapy of inflammatory diseases. Moreover, Dr. Cuzzocrea is also a co-inventor with Epitech group on the following patents:

  1. 1.

    EP 2 821 083

  2. 2.

    MI2014 A001495

  3. 3.

    102015000067344

No other authors have competing interests.

Reference

  1. Impellizzeri D, Bruschetta G, Cordaro M, Crupi R, Siracusa R, Esposito E, Cuzzocrea S. Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain. J Neuroinflammation. 2014;11:136. doi:10.1186/s12974-014-0136-0.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Ethics approval and consent to participate

The study [1] was approved by the University of Messina Animal Care Review Board: protocol number 8/U-apr 16.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Salvatore Cuzzocrea.

Additional information

The online version of the original article can be found under doi:10.1186/s12974-014-0136-0.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Impellizzeri, D., Bruschetta, G., Cordaro, M. et al. Erratum to: Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain. J Neuroinflammation 13, 129 (2016). https://doi.org/10.1186/s12974-016-0595-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12974-016-0595-6